Funny thing happened when H.225, the bill to decriminalize possession of single doses of buprenorphine, moved over to the Senate after passing the House by a lopsided 126-19 margin. For those just tuning in, buprenorphine is a prescription opioid that can be used instead of riskier street drugs. Vermont’s death toll from overdoses has been climbing for years, and the decrim bill could save a lot of lives.
The bill reached the Senate on April 14. It was referred, not to the Health Care or Judiciary committees, but to the Rules Committee. It has languished there ever since, as the days in this session dwindle down to a precious few. (Legislative leaders are aiming for adjournment in mid-May which, despite the snow, is only three weeks away.)
And the Rules Committee has no meetings on its schedule.
This looks for all the world like a stalling tactic, as if leadership has decided (for whatever reason) to prevent the bill from reaching the Senate floor. And maybe that’s what it is, although Senate President Pro Tem Becca Balint says otherwise. Sort of.
“I’ve been meeting with the Chairs of Judiciary and Health & Welfare to try to find a path forward for this bill given the late date that it came over from the House. We did not want to vote it out of Rules until we had a sense of how long testimony and due diligence would take. Health & Welfare and Judiciary are planning a joint hearing on the bill this coming week. We know we are in the midst of a horrible surge in opioid-related deaths and we want to take all measures to help address this emergency. The Chairs want to be certain that this bill will have that impact.”
That’s a written statement received Thursday afternoon in response to my inquiry. Let’s take a closer look, and then invite an expert to make the case for immediate passage of H.225.Continue reading